Week In Review: Henlius Out-Licenses Southeast Asia Rights For PD-1 Candidate In $692 Million Deal [Seeking Alpha]
Thermo Fisher Scientific Inc (TMO)
Last thermo fisher scientific inc earnings: 4/22 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
ir.thermofisher.com/investors/investor-overview/default.aspx
Company Research
Source: Seeking Alpha
Week In Review: Henlius Out-Licenses Southeast Asia Rights For PD-1 Candidate In $692 Million Deal Summary Shanghai Henlius Biotech announced a $692 million partnership with Kalbe Genexine Biologics for Southeast Asian rights to Henlius' PD-1 checkpoint inhibitor. Nanjing Frontier Bio will collaborate with Thermo Fisher Scientific to develop a novel treatment for human immunodeficiency virus. I-Mab, a China-US clinical-stage biopharma, announced a clinical research collaboration with MSD (Merck). Deals and Financings Shanghai Henlius Biotech (HK:2696) announced a $692 million partnership with Kalbe Genexine Biologics for Southeast Asian rights to Henlius' PD-1 checkpoint inhibitor (see story Blue Sail Medical (SHZ:2382) of Shandong and Biosensors, a subsidiary of Blue Sail, will pay $160 million to acquire New Valve Technology, a Swiss medical device company. NVT specializes in safe, cost-effective, minimally invasive heart valve replacements. Its Allegra transcatheter aortic valve re
Show less
Read more
Impact Snapshot
Event Time:
TMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TMO alerts
High impacting Thermo Fisher Scientific Inc news events
Weekly update
A roundup of the hottest topics
TMO
News
- From Mine to Line through End of Life, How Technology is Optimizing Battery Production [Yahoo! Finance]Yahoo! Finance
- Failure Analysis Equipment Market To Reach USD 8.7 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at Barclays PLC from $590.00 to $615.00. They now have an "equal weight" rating on the stock.MarketBeat
- Life Science Tools Market To Reach USD 400.2 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $600.00 to $610.00. They now have a "buy" rating on the stock.MarketBeat
TMO
Earnings
- 4/24/24 - Beat
TMO
Sec Filings
- 4/26/24 - Form 144
- 4/24/24 - Form 8-K
- 4/9/24 - Form ARS
- TMO's page on the SEC website